Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
National Institutes of Health Clinical Center (CC)
Affimed GmbH
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
Therapeutic Advances in Childhood Leukemia Consortium
Cedars-Sinai Medical Center
M.D. Anderson Cancer Center
West Virginia University
Northside Hospital, Inc.
Tessa Therapeutics
Thomas Jefferson University
University of Liege
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Icahn School of Medicine at Mount Sinai
Dartmouth-Hitchcock Medical Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Columbia University
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
M.D. Anderson Cancer Center
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
University of Chicago
Massachusetts General Hospital
Beth Israel Deaconess Medical Center